The mechanisms that coordinate the final mitotic divisions of terminally differentiated bone marrow (BM) erythroid cells with components of their structural and functional maturation program remain largely undefined. We previously identified phenotypes resembling those found in early-stage myelodysplastic syndromes (MDS), including ineffective erythropoiesis, morphologic dysplasia and BM hyper-cellularity, in a knock-in mouse model in which cyclin E mutations were introduced at its two Cdc4 phosphodegrons (CPDs) to ablate Fbw7-dependent ubiquitination and degradation. Here, we have examined the physiologic consequences of cyclin E dysregulation in BM erythroid cells during terminal maturation in vivo. We found that cyclin E protein levels in BM erythroid cells are dynamically regulated in a CPD-dependent manner and that disruption of Fbw7-dependent cyclin E regulation impairs terminal erythroid cell maturation at a discrete stage before enucleation. At this stage of erythroid cell maturation, CPD phosphorylation of cyclin E regulates both cell-cycle arrest and survival. We also found that normal regulation of cyclin E restrains mitochondrial reactive oxygen species (ROS) accumulation and expression of genes that promote mitochondrial biogenesis and oxidative metabolism during terminal erythroid maturation. In the setting of dysregulated cyclin E expression, p53 is activated in BM erythroid cells as part of a DNA damage response-type pathway, which mitigates ineffective erythropoiesis, in contrast to the role of p53 induction in other models of dyserythropoiesis. Finally, cyclin E dysregulation and ROS accumulation induce histone H3 lysine 9 hyper-methylation and disrupt components of the normal terminal erythroid maturation gene expression program. Thus, ubiquitin-proteasome pathway control of G1-to-S-phase progression is intrinsically linked to regulation of metabolism and gene expression in terminally differentiating BM erythroid cells.
INTRODUCTION
Antagonism between cell proliferation and differentiation is recognized in cells of diverse lineages, though the mechanistic basis for the apparent opposition between these states remains incompletely defined. In work performed over 20 years ago using murine leukemia cells with erythroid differentiation potential, enforced expression of the c-myc oncogene, which drives both cell growth and proliferation, was found to inhibit globin gene expression, supporting the paradigm that excessive pro-proliferative signaling disrupts normal hematopoietic differentiation. 1 On the other hand, differentiation of erythroid progenitor cells appears to require active cell division, as the CFU-erythroid-toproerythroblast transition requires DNA synthesis for removal of repressive histone marks from bivalent chromatin. 2 Moreover, the E2F transcription factors have essential functions in supporting both expansion and maturation of erythroid progenitors. 3, 4 Presumably, the activity of proliferation-promoting factors must be limited to ensure both expansion of the erythroid progenitor pool and timely exit from the mitotic cell cycle. Supporting this concept are observations made from retinoblastoma (Rb) knockout models. 5, 6 Cyclin E overexpression subverts Rb pathway function, promoting E2F activation and cell-cycle progression past Rbimposed G1 checkpoint controls. 7 Cyclin E protein abundance is negatively regulated by ubiquitin-mediated proteolysis, and the SCF Fbw7 ubiquitin ligase targets Cdk2-bound, phosphorylated cyclin E for proteasomal destruction. 8 Fbw7-mediated ubiquitination and proteolysis of Cdk2-bound cyclin E is triggered by multi-site phosphorylation of cyclin E within motifs called Cdc4 phosphodegrons (CPDs): in mouse cyclin E1, one N-terminal CPD centered on threonine-74 (T74) and a C-terminal CPD including threonine-393 (T393). 8, 9 Fbw7 regulation of its substrates, including cyclin E, can be disrupted by mutations in Fbw7, transcriptional and translational repression, and possibly in myelodysplastic syndromes (MDS), by hyper-methylation of the FBXW7 gene. [10] [11] [12] [13] To study the consequences of disabled cyclin E ubiquitination in vivo, we generated a knock-in mouse strain in which the wildtype cyclin E1 gene (Ccne1) was targeted by a dual phosphodegron mutation (cyclin E T74A T393A ). We previously found that cyclin E T74A T393A mice are anemic and their bone marrow (BM) erythroid cells exhibit hyper-proliferation, impaired maturation and dysplastic morphologies. 9 In this study, we have examined in detail the consequences of dysregulated cyclin E upon erythroid differentiation in vivo. We demonstrate that regulation of cyclin E has functions extending beyond proliferation control during terminal erythroid maturation, including restraining oxidative metabolism and reactive oxygen species (ROS) accumulation in late-stage BM erythroid precursor cells. Dysregulated cyclin E during erythroid cell maturation is associated with p53 activation, histone H3 lysine 9 hyper-methylation and altered erythroid gene expression. Thus, ubiquitin ligase pathway control of cyclin E expression integrates proliferation control with metabolic and transcriptional regulatory mechanisms during terminal cell differentiation.
RESULTS

Cyclin E protein levels are dynamically regulated during terminal erythroid maturation in vivo
To determine the temporal relationship of Fbw7-dependent cyclin E regulation to BM erythroid cell maturation in vivo, we compared wild-type and CPD-mutated cyclin E protein levels in distinct morphologic subpopulations, defined first using Ter119 and CD71 (Figure 1a ). We also used a recently described strategy for monitoring BM erythroid cells using expression of CD44 vs forward scatter (FSC), permitting improved separation of terminal maturation stages and demonstrating abnormal ratio of earlier to later stage cells as we observed previously with use of CD71 and Ter1119 (Figure 1b ). 9, 14 In wild-type mice, cyclin E protein expression increases significantly from the proerythroblast (R0/1 or I) to basophilic erythroblast stage (R2 or II/III). With further maturation toward orthochromatic erythroblasts we observe reduced cyclin E protein levels. The rise and subsequent modulation during terminal erythroid cell maturation of cyclin E protein expression are not accompanied by significant alteration in cyclin E mRNA levels ( Supplementary Figures 1a and b) . In contrast to wild-type cyclin E, we observe that high cyclin E T74A T393A protein levels are retained throughout terminal erythroid maturation (Figures 1a-c), without a significant increase in Ccne1 message compared with wild-type cells (Supplementary Figure 1c ). Together, these data are consistent with the concept that the Fbw7 ubiquitin ligase pathway, which requires phosphorylations at threonines 74 and 393 to maintain normal periodicity of cyclin E expression, 9 regulates cyclin E expression during terminal erythroid maturation. Figure 1 . Cyclin E protein regulation during terminal erythroid maturation is phosphorylation dependent. (a) Left-BM cells were sorted based upon the expression of CD71 and Ter119 and subpopulations collected for immunoblot and RNA analyses as shown in subsequent panels. Right-lysates were prepared from the indicated BM erythroid cells pooled from two wild-type mice and immunoblotted as shown. HDAC2 expression is used as a nuclear protein control for comparing the relative abundance of the cyclin E nucleoprotein in the different erythroid cell subpopulations, given the presence of enucleated cells within the R4 gate. (b) BM erythroid cells were isolated based on CD44 vs Ter119 expression or CD44 expression vs FSC within the Ter119-positive subset, 14 with relative abundances indicated for a representative, age-and sex-matched pair. (c) Cyclin E protein levels were determined in sorted CD44/Ter119 or CD44/FSC erythroid cell subsets shown in b by immunoblot (top) and quantified relative to HDAC2 (bottom).
Cyclin E dysregulation impairs cell-cycle arrest and cell survival at a discrete stage during terminal erythroid maturation To determine how impaired Fbw7-mediated cyclin E regulation alters cell-cycle kinetics during terminal erythroid maturation, we utilized Hoechst 33342 co-staining with CD44/Ter119/FSC. We observed that wild-type cells within population IV (orthochromatic erythroblasts, the final stage of nucleated erythroid cells) are arrested in G1 phase, whereas significant numbers of cyclin E T74A T393A cells within this gate remained in S/G2 phase (Figure 2a ). In addition to abnormal cell-cycle kinetics, significant numbers of cyclin E knock-in cells within population IV were apoptotic (Figure 2b) , consistent with the relative reduction in numbers of these cells and BM reticulocytes (population V), which we enumerated in a separate assay employing thiazole orange and Hoechst 33342 staining ( Figure 2c ). Therefore, inability to appropriately downregulate cyclin E protein expression specifically during the final stage of nucleated erythroid cell maturation results in defective cell-cycle arrest and increased cell death.
Disruption of Fbw7-dependent cyclin E regulation activates p53 in vivo
To understand the consequences of dysregulated cyclin E to erythroid cell gene expression in vivo, we first conducted microarray analyses of Ter119-positive (Ter119 þ ), CD71-high BM cells isolated from cyclin E T74A T393A mice and wild-type littermate controls. In unsupervised analysis of the most significant gene expression changes comparing knock-in with wild-type cells and using Gene set enrichment analysis (GSEA, Broad Institute 15 ), we identified prominent evidence of p53 activation (Supplementary Figure 2) . These findings were corroborated by immunoblot analyses performed in BM Ter119 þ cells (Figure 3a ), demonstrating induction of p53 and p21, associated with increased serine 345-phosphorylated Chk1 and serine 15-phosphorylated p53, which together with increased gH2AX phosphorylation ( Figure 3b ), resemble the oncogene-induced DNA damage response. 16, 17 Using quantitative real-time PCR (RT-PCR), we observed induction of canonical p53 gene targets promoting cell-cycle arrest and apoptosis in cyclin E T74A T393A Ter119 þ CD71high cells, as well as increased expression of target genes involved in the response to oxidative stress, including those encoding the sestrin oxidoreductase proteins ( Figure 3c ). 18, 19 With expression of ribosomal protein gene mutations to model those found in Diamond-Blackfan anemia, p53 is activated and has been shown to increase apoptosis and impair maturation of erythroid cells. 20, 21 Thus, we hypothesized that activated p53 may mediate cyclin E-associated dyserythropoiesis. To test this, we bred a conditional, floxed p53 allele (p53 fl ) 22 into cyclin E knock-in mice as well as the Mx1-Cre transgene, enabling p53 inactivation in BM progenitor cells by polyinosinic/polycytidylic acid (pIpC) treatment, following adoptive transfer to syngeneic, irradiated, wild-type recipients to ensure study of cell-autonomous phenotypes related to expression of the cyclin E knock-in allele. Unexpectedly, we found that acute p53 deletion in vivo worsened terminal maturation of cyclin E T74A T393A BM erythroid cells, as measured by proportion of Ter119 þ CD71-high vs Ter119 þ CD71-low cell populations ( Figure 3d ). In contrast, cyclin E wildtype recipients with acutely deleted p53 demonstrated no impairment of BM erythroid cell maturation ( Supplementary  Figure 3 ). In a separate adoptive transfer experiment in which wild-type and cyclin E knock-in donor hematopoietic stem cells (HSCs) bearing germline deletion of Trp53 or the wild-type allele were transplanted into wild-type recipients, we found that engrafted cyclin E T74A T393A ; p53-null HSC recipients had significantly fewer numbers of peripheral red blood cells (RBCs) and lower blood hemoglobin concentrations compared with recipients of cyclin E T74A T393A ; p53-intact HSCs (Figure 3e ). Our findings suggest that p53 activation promotes compensated erythropoiesis in cyclin E T74A T393A mice, rather than directly mediating the dyserythropoiesis phenotype associated with cyclin E deregulation.
Cyclin E dysregulation induces ROS accumulation in BM erythroid cells Several p53-regulated genes with anti-oxidant functions are induced in cyclin E T74A T393A BM erythroid cells ( Figure 3c ). Thus, we reasoned that cyclin E T74A T393A erythroid cells might contain elevated reactive oxidative species (ROS), and further, that the more severe defects in terminal erythroid maturation we found with p53 loss combined with dysregulated cyclin E could be related to exacerbated ROS levels (Figures 3d and e ). We first measured oxygen consumption rates (OCRs) directly in BM Ter119 þ cells isolated from cyclin E T74A T393A and wild-type mice and found increased OCR coupled to ATP production in the Figure 4a ). Rb-E2F complexes repress genes that promote mitochondrial oxidative metabolism, 23 including Tfam, which encodes a regulator of mitochondrial genome transcription that also maintains mitochondrial DNA (mtDNA) copy number. 24 We identified increased expression of Tfam in Ter119 þ , CD71-high cyclin E T74A T393A BM erythroid cells, in which we find Rb hyperphosphorylated compared with wild-type cells. In these cells, we also find high expression of Nrf1, which encodes a master regulator of mitochondrial function and biogenesis previously reported as highly expressed in Rb-null erythroid cells ( Figure 4b ). 6, 25 We next tracked cytosolic ROS levels in subsets of Ter119 þ BM erythroid cells, using either CD71 ( Figure 4c ) or CD44/FSC ( Supplementary Figure 4 ) expression to define distinct maturation compartments. 14 We found that wild-type erythroid cells exhibit steadily declining ROS levels during terminal maturation. In contrast, cyclin E knock-in BM erythroid cells retain abnormally high ROS levels, prominently within the Ter119/CD44/FSC subpopulation (IV) comprises largely reticulocytes and orthochromatic erythroblasts. 14 We also observed higher ROS levels with concomitant p53 deletion ( Figure 4c ), consistent with the hypothesis that p53 loss potentiates the increased ROS associated with dysregulated cyclin E.
Because ROS normally decline during terminal erythroid cell maturation (Figure 4c ), our findings of increased OCR and ROS levels in cyclin E T74A T393A BM cells could potentially represent skewing of maturation within specific subpopulations. To exclude this possibility, we measured mitochondrial ROS levels specifically in the nucleated cells within population IV and verified both increased mitochondrial superoxide in cyclin E T74A T393A cells and comparable orthochromatic erythroblast morphologies in sorted cells from both genotypes ( Figure 4d ). Finally, we assayed mtDNA of cyclin E T74A T393A primary erythroid cells for evidence of ROSassociated damage, using a PCR assay that detects mtDNA deletions. 26 Consistent with prior observations made under conditions of increased ROS levels, we observed reproducible increases in mtDNA lesions in cyclin E T74A T393A cells compared with wild-type controls (Figure 4e ). In toto, our data indicate that disabled cyclin E ubiquitination by the Fbw7 pathway in BM erythroid cells results in failure to restrain oxidative metabolism and ROS production during terminal maturation. Immunoblot analyses for cyclin E and components of the p53-dependent DNA damage response were performed using primary BM cell lysates prepared after immunomagnetic separation based on Ter119 expression. HSC70 is shown as loading control; phospho-Chk1 detection was performed using same lysates as rest of immunoblot, but these were electrophoresed separately. (b) DNA damage foci were enumerated in primary Ter119 þ BM cells of the indicated genotypes using serine 139-phosphorylated H2AX (gH2AX) detection by flow cytometry. A representative comparison from two independent experiments is shown. (c) Expression of the indicated p53 gene targets in Ter119 þ CD71-high erythroid cells was measured by RT-PCR. Each colored bar represents averaged value of triplicate RT-PCR assays from a single knock-in mouse, expressed relative to expression in cells from age-and sex-matched wild-type controls. (d) Erythroid maturation was studied in 10 wild-type recipient mice transplanted with 1 Â 10 6 cells of the indicated genotypes and 5 Â 10 5 wild-type (CD45.1) BM cells. Five weeks following engraftment (equivalent for wild-type and knock-in donor cells), half of the recipient mice were treated with pIpC, and 16 weeks later, recipients were euthanized for study. Ter119 vs CD71 immunophenotyping profiles from BMs are shown for two representative sets of mice along with PCR genotyping (far right) of BM cells demonstrating efficient excision of floxed p53 allele following pIpC injections (*non-specific amplicon generated by PCR). The P-values are calculated from paired t-test comparing ratios of low CD71 À , Ter119 þ and high CD71 À , Ter119 þ erythroid progenitors. (e) Mean peripheral RBC counts and hemoglobin concentrations are shown for recipients of purified HSCs isolated from donor mice, 3 months following transplantation (n ¼ 24). Engraftment measured by peripheral blood CD45.2-positive cell enumeration was found to be comparable across all donor HSC groups (70-87%). Right-100 Â micrographs of May-Grunwald/Giemsa-stained orthochromatic erythroblasts isolated using the gating employed for the Mitosox assays. (e) Top-ethidium bromide staining of the indicated mtDNA amplification products, resolved on agarose gels, is shown. The mtDNA templates were obtained from Ter119 þ BM cells isolated from two mice of each of the indicated genotypes. Bottom-quantification of Ter119 þ cell mtDNA amplification for three pairs of mice, performed using PicoGreen reagent, expressed relative to wild-type mtDNA amplification. Derivation of the calculation for the increase in mtDNA lesions per 10 kb is previously described, 26 using normalization to 117 base-pair (bp) mtDNA amplification product for mitochondrial copy number. Dysregulated cyclin E expression in vivo perturbs mitochondrial mass regulation during terminal erythroid maturation Given the potential for increased mitochondrial biogenesis in cyclin E knock-in BM erythroid cells, we measured their mitochondrial content. In the subpopulation of cyclin E T74A T393A erythroid cells for which we observed high ROS levels (IV), we observed modestly increased mitochondrial mass using a fluorescencebased assay. In more mature cyclin E T74A T393A BM erythroid cells (subpopulation V), however, we observe a distinct population with markedly increased mitochondrial mass (Figure 5a ). As part of their terminal maturation program, BM erythroid cells normally undergo mitochondrial clearance (mitophagy); 27,28 thus, our data suggest that cyclin E T74A T393A erythroid cells may also be prone to defective mitophagy. Consistent with this hypothesis, we observed higher numbers of circulating RBCs in cyclin E T74A T393A mice with retained mitochondria, using electron microscopy to directly visualize these ( Figure 5b ). We then evaluated the mechanism by which dysregulated cyclin E disrupts mitophagy in erythroid cells.
Notably, we discovered that late maturation stage Ter119 þ cells of cyclin E T74A T393A mice have impaired induction of Bnip3L (also known as Nix), which encodes a rate-limiting regulator of autophagic clearance in terminally differentiating erythroid cells. 27, 28 These results paralleled our findings of impaired beta-globin induction in these cells (Figure 5c ). We also observed subtle, but statistically significant, shortening in peripheral blood survival of cyclin E T74A T393A RBCs, compared with wild-type cells (13.6% relative reduction, Figure 5d ). These data suggest that the ineffective BM erythropoiesis phenotype we identified in cyclin E T74A T393A mice is also associated with diminished survival of circulating RBCs. Finally, despite their marked reduction in cyclin E T74A T393A BMs, circulating reticulocytes are mildly increased in the knock-in mice (Figure 5d ), likely due to massively increased splenic erythropoiesis. 9 Consistent with our BM studies, we find late-stage splenic erythroid cells (population IV) of cyclin E T74A T393A mice are reduced in number and have high total and mitochondrial ROS levels, compared with wild-type splenocytes (Supplementary Figure 5 ).
Dysregulated cyclin E expression and increased ROS induce histone H3 lysine 9 hyper-methylation during erythroid cell maturation and disrupt normal terminal erythroid gene expression Bnip3L was recently identified as a GATA-1 target gene; 29 thus, mitophagy is a component of the GATA-1-dependent erythroid differentiation program. To study further the impact of impaired cyclin E regulation by the Fbw7 ubiquitin ligase pathway upon regulation of gene expression during erythroid maturation, we utilized G1E-ER4 (G1ER) cells. This embryonic stem cell-derived Gata1-null hematopoietic progenitor line expresses the GATA-1-ER fusion protein, permitting conditional activation of terminal erythroid differentiation. 30 With stable expression of cyclin E mutated at its phosphodegrons at homologous sites to those targeted by the mouse knock-in mutations (cyclin E-AA), disabling interaction with the Fbw7 ubiquitin ligase, we recapitulate in G1ERs the erythroid phenotypes observed in vivo with the cyclin E T74A T393A mouse: deficient hemoglobinization, reduced Hbb-b1 and Bnip3L expression, increased numbers of cells in S phase and high levels of mitochondrial ROS, DNA damage, p53 activation and apoptosis ( Figure 6 ; Supplementary Figures 6a and b) . Despite no appreciable difference in nuclear GATA-1 abundance with cyclin E overexpression, GATA-1 occupancy at both Hbb-b1 and Bnip3L was reduced in cyclin E-AA compared with vector-transduced cells (Figure 7a, upper panel) . Thus, high cyclin E disrupts GATA-1-dependent gene regulation during terminal erythroid maturation. With administration of exogenous ROS using peroxide, differentiating G1ER cells exhibit defective Bnip3L and Hbb-b1 expression and deficient hemoglobinization (Figure 7b ). To understand how cyclin E-induced ROS might impair GATA-1 target gene expression without altering GATA-1 levels during terminal erythroid maturation, we next measured gross abundance of repressive chromatin marks that can indicate chromatin configurations that are less permissive for transcription factor accessibility to target genes. We identified dose-responsive increase in methylation at H3K9, but not at H3K27 (Figure 7c ). Thus, with direct introduction of ROS, erythroid cell maturation is impaired, and this is associated with H3K9 hyper-methylation. We also find H3K9 methylation increased in abundance by immunoblot in cyclin E T74A T393A BM erythroid cells (Figure 7d ). Next, with cyclin E overexpression in differentiating G1ER cells, we identified a temporal correlation between emergence of increased mitochondrial superoxide (at levels comparable to those seen with peroxide administration) and H3K9me2 and H3K9me3 induction (Figure 7e ). We also performed chromatin immunoprecipitation in differentiated G1ER cells and found increased H3K9me3 occupancy at the regions of Bnip3L and Hbb-b1 in which we identified reduced GATA-1 binding (Figure 7a , lower panels).
With G1ER cell differentiation in the setting of dysregulated cyclin E, we note decreasing H3K9me3 signal over the first 8 h of differentiation (similar to control cells), while ROS is at basal levels (Figure 7e ). During this time, we do not find evidence of cell proliferation ( Supplementary Figure 6c) , indicating that passive demethylation via synthesis of nascent chromatin does not account for the reduced abundance of hyper-methylated H3K9. At 24 h, increased ROS resulting from dysregulated cyclin E activity could drive increased H3K9 methylation either by hindering active demethylation, or alternatively by increasing methyltransferase activity directed at H3K9. In agreement with the former hypothesis, we discovered that endogenous H3K9 demethylation activity is greatly decreased in lysates prepared from differentiating G1ER cells expressing CPD-mutated cyclin E (or treated with peroxide), compared with controls ( Figure 7f ). Taken together, these data suggest that impaired ROS homeostasis driven by dysregulated cyclin E activity induces a repressive chromatin state by impairing the activity of H3K9 demethylases, which in turn interferes with normal execution of the terminal maturation gene expression program.
DISCUSSION
In our first description of hematopoietic abnormalities associated with disabled Fbw7-mediated cyclin E regulation in vivo, we noted a dominant erythroid phenotype and hypothesized that physiologic consequences of the cyclin E T74A T393A mutation would be greatest in those cell lineages in which the Fbw7 pathway has a critical, non-redundant role in regulating cyclin E expression. 9 Importantly, findings from a recent study of post-translational regulation of cyclin E in hepatic cells by the BTB-Cul3-Rbx1 ubiquitin ligase, which promotes phosphorylation-independent degradation of cyclin E, 31 suggested the Fbw7 pathway functions chiefly in undifferentiated cells, whereas differentiated cells utilize the BTB-Cul3-Rbx1-dependent pathway. 32 Our data indicate that at least in the erythroid lineage, the Fbw7 pathway is required for control of cyclin E expression in terminally differentiated cells, specifically as they transit in maturation past the basophilic erythroblast stage.
We propose that high levels of ROS, resulting from dysregulated expression of genes controlling mitochondrial biogenesis and oxidative metabolism, are key downstream mediators of ineffective (Figure 8 ). For one, the erythroid dominant phenotype we have found in our studies of hematopoiesis in the cyclin E T74A T393A strain may be, at least in part, due to the induction of ROS selectively in the erythroid lineage ( Supplementary Figure 7) . Next, with exogenous administration of peroxide achieving comparable intracellular ROS levels as with dysregulated cyclin E, we can induce heterochromatin and reduce hemoglobinization of differentiated erythroid cells. Additionally, with deletion of p53, which controls expression of genes involved in the anti-oxidant response, 19, 33 we observe both increased ROS and worsening of BM erythroid cell maturation in cyclin E T74A T393A mice. Figure 7 . Increased ROS, induced by cyclin E or exogenously administered, induces histone H3 lysine 9 hyper-methylation in differentiated erythroid cells and disrupts GATA-1 interactions with target genes. (a) Chromatin immunoprecipitation (ChIP) analysis of GATA-1 occupancy at the Hbb-b1 promoter and Bnip3L (first intron) and a 10-kb downstream region was performed in G1ER cells transduced with the indicated constructs and induced for differentiation for 24 h. Enrichment, relative to IgG control, is shown for one representative of three independent sets of transductions and ChIPs. Corresponding enrichment for tri-methylated H3K9 (H3K9me3) at each gene is displayed below GATA-1 occupancy data. Inset shows immunoblot demonstrating comparable nuclear GATA-1 protein expression. (b) Expression of Hbb-b1 and Bnip3L was measured in differentiated G1ER cells, following treatment with hydrogen peroxide (H 2 O 2 ) at the indicated doses. Exogenous peroxide was added 8 h after induction of differentiation with beta-estradiol, and cells were collected at 48 h. Non-viable cells were excluded from collection by detecting retained propidium iodide. Inset shows cell pellets with H 2 O 2 administration at the indicated doses (in mM). (c) Lysates were prepared from differentiated G1ER cells, following treatment with H 2 O 2 , for immunoblot assays. Quantitation of each histone modification was performed with normalization to total H3 signal. A representative result from three independent experiments is shown. Mean increases in Mitosox signal relative to untreated cells were obtained using FlowJo and are expressed relative to untreated control. (d) Ter119 þ BM cell lysates from mice of the indicated genotypes were electrophoresed and immunoblotted as shown. Total H3 is shown as a loading control. Displayed data are representative of three independent experiments. (e) G1ER cells, transduced as shown, were collected at the indicated time points during erythroid differentiation then lysed for immunoblot analyses (en, endogenous cyclin E signal; *, retrovirally expressed cyclin E). Mitochondrial superoxide levels during differentiation were measured as in Figure 4d and mean Mitosox signal calculated for cyclin E-AA-transduced cells is expressed relative to the corresponding MIGR1-transduced cell time point. (f ) Endogenous H3K9 demethylation activity was measured in lysates prepared from G1ER cells transduced or treated as indicated after differentiation in culture for the indicated times, using a quantitative fluorometric assay. Cyclin E(AA)-transduced cell lysates yielded readings above substrate-free baseline readings, though activity calculated using formula described in Materials and methods obtains negative value. Results displayed are from a representative assay of two independent experiments. Interestingly, in contrast to our prior studies performed in primary fibroblasts in culture, 34, 35 p53 and p21 induction by deregulated cyclin E in erythroid cells in vivo is not associated with inhibition of cyclin E-associated kinase activity ( Supplementary Figure 8a) , consistent with our observations of defective G1 arrest during terminal maturation of cyclin E T74A T393A erythroid cells (Figure 2a ). Our data suggest that H3K9 hyper-methylation is linked to increased ROS levels, and in ongoing studies, we are attempting to elucidate the mechanistic basis for impaired H3K9 demethylase activity we find associated with dysregulated cyclin E and high ROS. Expression analyses of H3K9 demethylase genes in primary, cyclin E T74A T393A erythroid cells (population IV) reveal several are expressed at reduced levels compared with control cells (Supplementary Figure 8b) , consistent with decreased overall endogenous H3K9 demethylase activity identified in differentiating G1ER cells expressing Fbw7-resistent cyclin E or treated with exogenous ROS (Figure 7f ). Notably, we were able to reduce physiologic ROS during differentiation in G1ER cells by treatment with vitamin C, and this is associated with decreased H3K9me3 levels, further supporting the concept of a functional link between ROS and H3K9 methylation. However, we found that ROS in cyclin E overexpressing G1ER cells was unable to be reduced to basal levels, and in turn, H3K9 methylation levels were unresponsive ( Supplementary Figure 9b) . Moreover, we tried unsuccessfully to reduce ROS in cyclin E T74A T393A erythroid cells in vivo to enhance erythroid maturation by administering Nacetylcysteine using a dosing strategy previously found to reduce ROS in hematopoietic progenitor cells 36 (Supplementary Figures  9c and d) . Thus, a single pharmacologic strategy (for example, increasing intracellular glutathione) is insufficient to counteract the multiple pathways by which unrestrained cyclin E activity generates high ROS levels during terminal erythroid maturation, including increasing oxidative metabolism and mitochondrial mass and inducing mtDNA lesions, which themselves can be ROS productive. 37 Much of the work focusing on Fbw7 in malignant hematopoiesis has centered on functions of Notch and c-Myc (both targets of the SCF Fbw7 ) in T-cell acute lymphoblastic leukemias associated with loss-of-function mutations in Fbw7. 38, 39 High cyclin E activity could drive dyserythropoiesis phenotypes in clinical entities such as MDS, as expression of FBXW7 could be modulated in the myeloid/erythroid lineage by a variety of mechanisms, including microRNA-mediated repression of transcription/translation, 40 transcriptional repression 10 and gene hyper-methylation. 11 The potential implications of our findings extend beyond cyclin E-centered pathogenic mechanisms, though, as increased ROS driven by expression of multiple oncogenes 41 could directly contribute to ineffective erythropoiesis in MDS. Further detailed study of primary patient samples will be required to understand the precise contribution of defects in oxidative metabolism control and ROS homeostasis to the molecular pathogenesis of MDS and related diseases.
MATERIALS AND METHODS Mice
Generation of the cyclin E T74A T393A knock-in strain was previously described. 9 C57BL/6 CD45.1 congenic mice and Trp53-mutant mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Mx1-Cre transgenic mice were provided by Dr John Crispino (Northwestern University). 42 The Northwestern University IACUC approved all mouse studies. All mice were genotyped by PCR using published protocols.
BM transplantation
CD45.1 recipients were placed on Bactrim-containing water for 1 week before irradiation with a total of 1100 rads divided over two equal fractions (separated by 4 h) the day before transplantation. For transplant of p53floxed bone marrow cells, 1 Â 10 6 total nucleated BM cells (CD45.2 þ ) from Mx1-Cre; p53fl/fl; cyclin E wt or Mx1-Cre; p53fl/fl; cyclin E T74A T393A mice, along with 0.5 Â 10 6 CD45.1 þ whole BM support cells, were injected retroorbitally. Five weeks after transplantation, peripheral blood was obtained and stained with CD45.1 and CD45.2 antibodies to verify donor cell engraftment. A subset of the recipients was injected with pIpC (GE Healthcare, Little Chalfont, UK; 10 mg/g body weight) every other day for five doses, whereas the remainder served as untreated controls. Mice were killed 16 weeks after pIpC administration for phenotypic analysis. For transplants of purified HSCs, recipient mice (CD45.1) irradiated as previously described were administered via retro-orbital sinus injection of 50 HSCs (CD45.2 donors) of the following immunophenotype: lineage negative (depletion utilized EasySep hematopoietic progenitor kit; STEMCELL Technologies, Vancouver, BC, Canada), Sca-1 and c-kit positive, CD34 and CD48 negative and CD150 positive. In all, 3 Â 10 5 lin þ , Sca-1negative BM cells (CD45.2) were used as support cells. 43 Recipient engraftment was monitored monthly along with complete blood counts.
Plasmids and antibodies
Human cyclin E cDNA, containing phosphodegron mutations (cyclin E-AA) homologous to the mouse cyclin E T74A T393A mutation, was previously generated by site-directed mutagenesis and subcloned into the MIGR1 vector for expression in G1E-ER4 cells. 30 Antibodies used are detailed in Supplementary Methods as are immunoblot and chromatin immunoprecipitation methodologies.
Cell culture G1E-ER4 (G1ER) cells were cultured in IMDM (Life Technologies, Carlsbad, CA, USA) with 15% fetal bovine serum, 2% penicillin/streptomycin solution (Life Technologies), 1:100 000 monothioglycerol (Sigma, St Louis, MO, USA), erythropoietin (10 000 U/ml; Amgen, Thousand Oaks, CA, USA) and CHO-KL conditional media (1:200) . For differentiation, beta-estradiol (Sigma) was added to a final concentration of 10 -7 M in culture media for 24-48 h. For retroviral transduction, cells were spinoculated with retroviral supernatants, prepared by transfecting Phoenix cells (G Nolan, Stanford) using calcium phosphate precipitation method, and 4 mg/ml polybrene for 90 min at room temperature. Vitamin C (Sigma) was added to G1ER cells to counteract ROS at a dose of 200 mM at 8 h following beta-estradiol induction of differentiation. Activation of p53 in response to dysregulated cyclin E expression is represented as well as its activity to counteract ROS through induction of several downstream target genes with anti-oxidant functions. 19, 33 Fbw7 regulates terminal erythroid maturation Y Xu et al
Gene expression analyses
For quantitative RT-PCR, RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcribed using the AffinityScript qPCR cDNA synthesis kit (Agilent Technologies, Santa Clara, CA, USA). For microarray analysis, RNA was extracted from sorted BM erythroid cells using Trizol followed by DNase treatment and cleanup with RNeasy MinElute Cleanup Kit (Qiagen). Microarray analysis was performed using Mouse WG-6 v2 Expression BeadChips (Illumina, San Diego, CA, USA). Microarray hybridization was performed for cDNA from three littermate pairs of wild-type and cyclin E T74A T393A mice. Data were analyzed subsequently using GeneSpring (Agilent) and Gene Set Enrichment Analysis software (GSEA, Broad Institute 15 ). Raw data are accessible at NCBI Gene Expression Omnibus (ID GSE45135). Quantitative real-time PCRs were performed using SYBR Green Mix (Roche, Penzberg, Germany) on a LightCycler 480 machine (Roche). Expression levels of target mRNA transcripts were normalized to either Gapdh or Actn1. Primer sequences are available upon request.
Hematopoietic analyses
BM cells were harvested from bilateral femurs and tibiae and resuspended in phosphate-buffered saline/2% fetal bovine serum. For erythroid immunophenotyping, RBC lysis was not performed. For RNA isolation from primary erythroid precursors, BM cells were antibody stained then collected using a MoFlo cell sorter (Dako, Carpinteria, CA, USA). For separation of Ter119 þ cells from whole BM, cells were incubated with PE-Ter119 antibody then immunomagnetic beads (PE Selection Kit; STEMCELL Technologies). For cell-cycle studies, cells were either fixed in 70% ethanol, washed, and incubated in RNAse A þ 10 mg/ml DAPI (Sigma) or labeled with Hoechst 33342 (Sigma) for live-cell analysis. Cell-cycle analyses were performed using FlowJo software (Tree Star, Ashland, OR, USA) and Dean-Jett-Fox modeling. Complete blood count analyses from peripheral blood were performed on Hemavet HV950FS (Drew Scientific, Dallas, TX, USA).
Erythrocyte lifespan determination
In vivo clearance of peripheral RBCs was determined as described previously 44 with minor modifications. RBCs from wild-type or cyclin E T74A T393A mice were labeled with 10 mM CFSE (Invitrogen) for 30 min at 37 1C, washed with sterile phosphate-buffered saline, and resuspended at a density of 1 Â 10 9 cells in 0.1 ml. Mice were injected with CFSE-labeled RBCs, and blood samples were collected from tail veins periodically and analyzed by flow cytometry. Slopes of rate of turnover were calculated to enable half-life determination, and statistical significance of difference calculated using Prism (GraphPad, San Diego, CA, USA).
Metabolic analyses
To measure OCRs, we utilized a Seahorse XF24-3 Extracellular Flux Analyzer (Seahorse Bioscience. North Billerica, MA, USA). BM cells enriched for Ter119 (by depleting whole BM for all lineage markers except Ter119) were seeded in 24-well plate pre-coated with Cell-TaK (BD Biosciences, East Rutherford, NJ, USA) in unbuffered DMEM with 0.1% of fetal bovine serum. Before taking readings, cells were incubated for 1 h without CO 2 , then baseline OCR was measured. Readings were then obtained following injection of oligomycin (5 mM), FCCP (10 mM) and rotenone (2 mM), together with actinomycin A (2 mM). Coupled OCR represents ATP-linked OXPHOS, indicated by the difference in readings before and after injection of oligomycin. For ROS detection in BM cells, cells were stained with PE-CD71 and APC-Ter119, then incubated with 10 mM cell-permeable 2 0 ,7 0 -dichlorodihydrofluorescein (CM-H 2 DCFDA) (Life Technologies) in dye-free Hank's Balanced Salt Solution (HBSS; Life Technologies) for 30 min at 37 1C and analyzed immediately.
Mitochondrial assays
For mitochondrial mass analyses, live cells were stained either with PE-CD71 or with APC-Ter119 and then incubated with 100 nM MitoTracker reagent for 20 min at 37 1C. To detect mitochondrial superoxide, BM cells were stained with FITC-CD71 and APC-Ter119 and then incubated with 5 mM Mitosox (Molecular Probes) for 15 min at 37 1C in HBSS and analyzed immediately. For quantification of mtDNA instability, total cellular DNA was purified using Gentra Puregene kit (Qiagen) from Ter119-selected BM cells. PCR was performed and lesion burden quantified using PicoGreen dsDNA detection reagent as previously described. 26 For transmission electron microscopy, RBCs were fixed in 0.1 M sodium cacodylate buffer with 2% paraformaldehyde and 2.5% glutaraldehyde, embedded and sectioned at Northwestern University Cell Imaging Facility. Images were obtained using a Spirit G2 microscope (FEI Tecnai, Hillsboro, OR, USA).
H3K9 demethylation assays
A fluorometric assay was used (Cayman Chemical, Ann Arbor, MI, USA) for detection of endogenous Jumonji C domain demethylases activity in 1 Â 10 8 G1ER cells, lysed in 0.1 ml phosphate-buffered saline supplemented with protease inhibitors, using two 20-s sonication pulses. H3K9me3contaning peptide was used as a substrate, and purified JMJD2D was used for positive control. Demethylase activity (nmol/min per ml) was calculated as follows: ((corrected sample fluorescence À (y intercept))/standard curve slope (corrected fluorescence/mM) Â 30 min) Â sample dilution factor.
